Trial reportNature2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Abstract readRandomized Controlled TrialClinical Trial, Phase IIClinical Trial, Phase III
In one paragraph
Trial report in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Safety and tolerability of PARP inhibitors in cancer patients: a network meta-analysis of randomized controlled trials.BMC cancer · 2026Pooled it
- Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?Breast cancer research and treatment · 2026Pooled it
- Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.Nature communications · 2025Trial
- Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer.Acta pharmacologica Sinica · 2026Review
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
- Neoadjuvant therapy for stage II-III triple-negative breast cancer: Current evidence, clinical boundaries and emerging strategies (Review).Oncology letters · 2026Review
- Current and future therapies for triple-negative breast cancer.Journal of hematology & oncology · 2026Review
- LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.Molecular cancer therapeutics · 2026Article
- Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.NPJ breast cancer · 2026Review
- m6A modified circPTK2 mediates TNBC chemotherapy resistance.Translational cancer research · 2026Article
- Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective.Biomarker research · 2026Review
- Tumor microenvironment transcriptional activity enables robust stratification of chemotherapy response in triple-negative breast cancer.Cell reports. Medicine · 2026Article
- Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy.Cancers · 2026Review
- Review
- Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment Nephrectomy.medRxiv : the preprint server for health sciences · 2025Article
- ZNF526 drives tumor growth by enhancing SHMT1-dependent serine metabolism and antioxidant capability in TNBC.Molecular cancer · 2025Article
- Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer.Molecular oncology · 2025Article
- Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy forInternational journal of molecular sciences · 2025Review
- Triple-Negative Breast Cancer Unveiled: Bridging Science, Treatment Strategy, and Economic Aspects.International journal of molecular sciences · 2025Review
- Gene context drift identifies drug targets to mitigate cancer treatment resistance.Cancer cell · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Jean E AbrahamPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK. ja344@cam.ac.uk.ORCID 0000-0003-0688-4807
Karen PinillaPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-2723-0805
Alimu DayimuCambridge Cancer Trials Centre, University of Cambridge, Cambridge, UK.
Louise GrybowiczCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Nikolaos DemirisDepartment of Statistics, Athens University of Economics and Business, Athens, Greece.
Caron HarveyCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Lynsey M DrewettRoyal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
Rebecca LuceyPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-6226-447X
Alexander FultonPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Anne N RobertsCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Joanna R WorleyPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Anita ChhabraCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-9899-8010
Wendi QianCambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-4238-3471
Anne-Laure VallierCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Richard M HardyCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Steve ChanThe City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Tamas HickishRoyal Bournemouth General Hospital, Bournemouth, UK.
Devashish TripathiRoyal Wolverhampton NHS Trust, Wolverhampton, UK.
Ramachandran VenkitaramanIpswich Hospital, East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK.
Mojca PersicUniversity Hospital of Derby and Burton, Derby, UK.
Shahzeena AslamBedford Hospital, Bedfordshire Hospitals NHS Foundation Trust, Bedford, UK.
Daniel GlassmanPinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Wakefield, UK.
Sanjay RajUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
Annabel BorleyVelindre Cancer Centre, Cardiff, UK.
Jeremy P BraybrookeUniversity Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Stephanie SutherlandMount Vernon Cancer Centre, Northwood, UK.
Emma StaplesQueens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK.
Lucy C ScottBeatson West Of Scotland Cancer Centre, Glasgow, UK.
Mark DaviesSwansea Bay University Health Board, Swansea, UK.
Cheryl A PalmerHinchingbrooke Hospital, North West Anglia NHS Foundation Trust, Huntingdon, UK.
Margaret MoodyMacmillan Unit, West Suffolk Hospital NHS Foundation Trust, Bury Saint Edmunds, UK.
Mark J ChurnWorcestershire Acute Hospitals NHS Trust, Worcester, UK.
Jacqueline C NewbyRoyal Free London NHS Foundation Trust, London, UK.
Mukesh B MukeshOncology Department, Colchester General Hospital, East Suffolk & North Essex NHS Trust, Colchester, UK.
Amitabha ChakrabartiUniversity Hospitals Dorset NHS Foundation Trust, Poole, UK.
Rebecca R RoylanceUniversity College London Hospitals NHS Foundation Trust, London, UK.
Philip C SchoutenDepartment of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Nicola C LevittOxford University Hospital NHS Foundation Trust, Oxford, UK.
Karen McAdamPeterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK.
Anne C ArmstrongThe Christie NHS Foundation Trust and Division of Cancer Sciences, Manchester, UK.
Ellen R CopsonCancer Sciences Academic Unit, University of Southampton, Southampton, UK.
Emma McMurtryEMC2 Clinical Consultancy, Sale, Manchester, UK.
Marc TischkowitzDepartment of Medical Genetics, National Institute for Health Research, Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.ORCID 0000-0002-7880-0628
Elena ProvenzanoDepartment of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Helena M EarlPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyPhthalazinesPiperazinesTriple Negative Breast NeoplasmsAdolescentAdultAgedAnthracyclinesBRCA1 ProteinBRCA2 ProteinCarboplatinFemaleGenes, BRCA1Genes, BRCA2HumansAnthracyclinesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCarboplatinolaparibPaclitaxelPhthalazinesPiperazines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.